(TheNewswire)
IntegratedAdvisory and Investor Relations Program to Focus on ElevatingCompany’s Visibility in US Capital Markets Ahead of ProjectedCorporate Milestones
LONDON, ONTARIO - TheNewswire- September 29, 2021 - Sernova Corp. (TSXV:SVA)(OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage leader in regenerativemedicine and cell therapy therapeutics developing a potential“functional cure” for type 1 diabetes (T1D) and other chronicdiseases, announced today it has engaged NewYork-based LifeSci Advisors LLC, a leading investor relationsconsultancy firm serving life science companies. LifeSci is aninvestor relations consultancy that will provide institutionalinvestor communications and capital markets outreach services to helpSernova achieve its capital markets objectives via a broad array ofinitiatives.
With a global presence, LifeSci Advisors ( www.lifesciadvisors.com ) providescomprehensive services d esigned to increase its clients’visibility within the investment community and to educateinstitutional investors about the Company. The LifeSciteam has substantial experience in equity capital markets andthe life science industry, with long-standing relationships amongleading institutional investors and senior corporate professionalsthat it leverages on behalf of its clients.
“We are delighted to engage LifeSci during thisexciting time for Sernova,” said Dr. Philip Toleikis, President andCEO of Sernova. “With multiple potential value-creating milestoneson the horizon, it is important for us to clearly communicate ourvalue proposition to investors and the industry as we work towardachieving major inflection points. We believe LifeSci has the rightteam and approach to help us reach the appropriate institutionalaudience on a global scale, which has the potential to createsubstantial shareholder value as we execute against our clinical andbusiness objectives.”
The engagement is subject to TSX Venture Exchangeacceptance. Under the terms of the engagement, LifeSci Advisors willbe engaged for an initial term of up to 12 months, which may berenewed by the parties. In addition to reimbursement of reasonableout-of-pocket expenses, Sernova will pay LifeSci Advisors a servicesfee of US$210,000.
ABOUT SERNOVA
Sernova is developing regenerative medicine therapeutic solutionsusing a medical device (Cell Pouch™) and immune protectedtherapeutic cells/tissues (i.e., human donor cells, corrected humancells and stem cell-derived cells) to improve the treatment andquality of life of people with chronic metabolic diseases such asinsulin-dependent diabetes, blood disorders including hemophilia, andother diseases treated through cellular production of proteins orhormones missing or in short supply within the body. For moreinformation, please visit www.sernova.com .
ABOUT SERNOVA’S CELL POUCHSYSTEM
The Cell Pouch, as part of the Cell Pouch System, is a novel,proprietary, scalable, implantable macro- encapsulation devicesolution designed for the long-term survival and function oftherapeutic cells. The device upon implantation is designed toincorporate with tissue, forming highly vascularized tissue chambersfor the transplantation and function of therapeutic cells, which thenrelease proteins and hormones as required to treat disease.
The Cell Pouch, along with therapeutic cells, has been shown toprovide long-term safety and efficacy in small and large animal modelsof diabetes and has been proven to provide a biologically compatibleenvironment for insulin-producing cells in humans in a Canadianfirst-in-human study. Sernova is currently conducting a Phase I/IIstudy at the University of Chicago. Positive initial results have beenpresented at several international scientific conferences.
FOR FURTHER INFORMATION, PLEASECONTACT:
Investors:
Corey Davis, Ph.D.
LifeScience Advisors, LLC
212-915-2577
Corporate:
Investor Relations Sernova Corp.
Tel: (519) 858-5126
investor.relations@sernova.com
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are notrecitations of historical facts, may constitute “forward-lookingstatements” that involve various risks, uncertainties, andassumptions, including, without limitation, statements regarding theprospects, plans, and objectives of the company. Wherever possible,but not always, words such as "expects", "plans","anticipates", "believes", "intends","estimates", "projects", "potential for"and similar expressions, or that events or conditions"will", "would", "may","could" or "should" occur are used to identifyforward-looking statements. These statements reflect management’sbeliefs with respect to future events and are based on informationcurrently available to management on the date such statements weremade. Many factors could cause Sernova’s actual results,performances or achievements to not be as anticipated, estimated orintended or to differ materially from those expressed or implied bythe forward-looking statements contained in this news release. Suchfactors could include, but are not limited to, the company’s abilityto secure additional financing and licensing arrangements onreasonable terms, or at all; ability to conduct all requiredpreclinical and clinical studies for the company’s Cell Pouch Systemand/or related technologies, including the timing and results of thosetrials; ability to obtain all necessary regulatory approvals, or on atimely basis; ability to in-license additional complementarytechnologies; ability to execute its business strategy andsuccessfully compete in the market; and the inherent risks associatedwith the development of biotechnology combination products generally.Many of the factors are beyond our control, including those caused by,related to, or impacted by the novel coronavirus pandemic. Investorsshould consult the company’s quarterly and annual filings availableon www.sedar.com for additional information on risks and uncertaintiesrelating to the forward-looking statements. Sernova expresslydisclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information,future events or otherwise.
Copyright (c) 2021 TheNewswire - All rights reserved.